Rightly so, the Q1 numbers showed revenue increasing over 80% pcp but the 1H numbers are up around 65% pcp. This means the growth in Q2FY22 vs Q2FY21 was was only around 40%. Ballpark numbers but that's what I think disappointment the market. I am happy giving them the benefit of doubt. Compared to a lot of spec health stocks, PEB looks like they have a beneficial solution. As long as the product is actually going to save the healthcare system money, I'm sure it will eventually get adopted more broadly.
PEB Price at posting:
$1.32 Sentiment: Hold Disclosure: Held
